share_log

Medtronic | 10-Q: Q2 2025 Earnings Report

Medtronic | 10-Q: Q2 2025 Earnings Report

美敦力 | 10-Q：2025财年二季报
美股SEC公告 ·  2024/11/27 05:18

Moomoo AI 已提取核心信息

Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.
Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.
美敦力报告了2025财年第二季度的稳健业绩，营业收入增长5%至84亿美元，摊薄后每股收益增长46%至0.99美元。这一增长得益于大多数业务的强劲表现，尤其是在糖尿病（+12%）、神经科学（+7%）和心血管（+6%）领域。国际市场增长强劲，增长率为8%，而美国营业收入增长3%。营业利润增长19%，达到16亿美元，税率为18.0%，相比去年同期的30.6%大幅下降。公司保持强劲的流动性，季度末现金及现金等价物为14亿美元，流动投资为66亿美元。在本季度，美敦力以平均价格86.26美元回购了290万股股票。展望未来，管理层将继续专注于创新和市场拓展，同时关注包括竞争压力、地域发展和供应链约束等宏观挑战。公司强调了关键增长驱动因素的持续动能，包括MiniMed 780G胰岛素泵系统、Inceptiv脊髓刺激器和Hugo机器人手术平台。
美敦力报告了2025财年第二季度的稳健业绩，营业收入增长5%至84亿美元，摊薄后每股收益增长46%至0.99美元。这一增长得益于大多数业务的强劲表现，尤其是在糖尿病（+12%）、神经科学（+7%）和心血管（+6%）领域。国际市场增长强劲，增长率为8%，而美国营业收入增长3%。营业利润增长19%，达到16亿美元，税率为18.0%，相比去年同期的30.6%大幅下降。公司保持强劲的流动性，季度末现金及现金等价物为14亿美元，流动投资为66亿美元。在本季度，美敦力以平均价格86.26美元回购了290万股股票。展望未来，管理层将继续专注于创新和市场拓展，同时关注包括竞争压力、地域发展和供应链约束等宏观挑战。公司强调了关键增长驱动因素的持续动能，包括MiniMed 780G胰岛素泵系统、Inceptiv脊髓刺激器和Hugo机器人手术平台。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Venus Concept
    VERO
    -- 0.5400
    AdaptHealth
    AHCO
    -- 10.640
    Bluejay Diagnostics
    BJDX
    -- 4.2200
    BIOSIG TECHNOLOGIES INC
    BSGM
    -- 1.0800
    英特格拉生命科学
    IART
    -- 24.720
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！